<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Arch. Toxicol</journal-id><journal-title-group><journal-title>Archives of Toxicology</journal-title></journal-title-group><issn pub-type="ppub">0340-5761</issn><issn pub-type="epub">1432-0738</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7138655</article-id><article-id pub-id-type="publisher-id">2734</article-id><article-id pub-id-type="doi">10.1007/s00204-020-02734-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Guest Editorial</subject></subj-group></article-categories><title-group><article-title>COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boeckmans</surname><given-names>Joost</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Robim M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Demuyser</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pi&#x000e9;rard</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Vanhaecke</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rogiers</surname><given-names>Vera</given-names></name><address><email>vera.rogiers@vub.be</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.8767.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2290 8069</institution-id><institution>Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, </institution><institution>Vrije Universiteit Brussel, </institution></institution-wrap>Laarbeeklaan 103, 1090 Brussels, Belgium </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411326.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0626 3362</institution-id><institution>Department of Microbiology, </institution><institution>Universitair Ziekenhuis Brussel, </institution></institution-wrap>Laarbeeklaan 101, 1090 Brussels, Belgium </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>4</month><year>2020</year></pub-date><fpage>1</fpage><lpage>3</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions></article-meta></front><body><p id="Par1">In December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in the Chinese province of Wuhan and rapidly infected hundreds of thousands of people worldwide. Infected patients mostly exhibit general signs of pneumonia (fever, dyspnea, coughing and desaturation) and a presumably significant number of infected patients are asymptomatic. Yet, about 5&#x02013;10% of patients develop critical oxygen deprivation, needing intensive care and intubation with mechanical ventilation (Huang et al. <xref ref-type="bibr" rid="CR15">2020</xref>; Raoult et al. <xref ref-type="bibr" rid="CR24">2020</xref>). Typical acute phase laboratory findings are present in admitted COVID-19 patients, <italic>e.g.</italic> elevated c-reactive protein and ferritin. Also, lactate dehydrogenase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are often elevated in COVID-19 patients, indicating liver damage (Zhou et al. <xref ref-type="bibr" rid="CR30">2020</xref>). Recent reports point to the fact that liver injury, by means of increased aminotransferase levels, more frequently occurred in severe COVID-19 cases compared to patients with mild symptoms (Zhang et al. <xref ref-type="bibr" rid="CR29">2020</xref>; Guan et al. <xref ref-type="bibr" rid="CR12">2020</xref>; Liu et al. <xref ref-type="bibr" rid="CR17">2020a</xref>, <xref ref-type="bibr" rid="CR18">b</xref>; Chen et al<italic>.</italic><xref ref-type="bibr" rid="CR7">2020</xref>).</p><p id="Par2">SARS-CoV-2 enters the cell by binding onto angiotensin-converting enzyme 2 (ACE2) (Gurwitz <xref ref-type="bibr" rid="CR13">2020</xref>). Until today, no strong evidence is present that ACE2 is expressed in the liver, although a recent, non-peer reviewed, article reported its expression in cholangiocytes (Hamming et al. <xref ref-type="bibr" rid="CR14">2004</xref>; Chai et al. <xref ref-type="bibr" rid="CR6">2020</xref>).</p><p id="Par3">Retrospective analysis of the earlier-reported SARS-CoV, causing the &#x02018;severe acute respiratory syndrome (SARS)&#x02019; and also infecting humans via ACE2, showed that the disease was accompanied&#x000a0;by abnormal liver function which could be due to viral replication in the liver (Cui et al. <xref ref-type="bibr" rid="CR8">2004</xref>). It is indeed known that multiple (respiratory) viruses can disrupt liver functions via (CD8&#x02009;+) immune cell-mediated reactions (Adams and Hubscher <xref ref-type="bibr" rid="CR1">2006</xref>).</p><p id="Par4">It has been reported that patients suffering from certain viral infections, such as infections caused by hepatitis C and human immunodeficiency viruses, are more prone for developing drug-induced liver injury (DILI), especially when associated with highly active anti-retroviral therapy (Naidoo et al. <xref ref-type="bibr" rid="CR23">2019</xref>; Bonacini <xref ref-type="bibr" rid="CR5">2004</xref>). Recently it was postulated that liver impairment in COVID-19 patients could also be drug-related (Zhang et al. <xref ref-type="bibr" rid="CR29">2020</xref>). This may have consequences for patients who are treated with novel, potentially hepatotoxic, antiviral drugs and perhaps also antibiotics for bacterial superinfections (Xu et al<italic>.</italic><xref ref-type="bibr" rid="CR27">2020a</xref>, <xref ref-type="bibr" rid="CR28">b</xref>). Hydroxychloroquine is applied as an antiviral drug, with sparse evidence in small clinical settings. Yet, viral replication and disease progression would be reduced and overall survival would increase. The effect of hydroxychloroquine on hepatic tissue seems ambiguous, since it is used to treat liver infection with protozoa (<italic>i.e.</italic> malaria) but cases of fulminant hepatic failure have been reported (Makin et al. <xref ref-type="bibr" rid="CR19">1994</xref>; Liu et al<italic>.</italic><xref ref-type="bibr" rid="CR17">2020a</xref>). Azithromycin would have additional effects to hydroxychloroquine. However, there is little evidence and the underlying mechanisms are unclear (Gautret et al. <xref ref-type="bibr" rid="CR11">2020</xref>). Furthermore, azithromycin-induced hepatotoxicity only appears 1&#x02013;3&#x000a0;weeks after azithromycin initiation (Martinez et al. <xref ref-type="bibr" rid="CR20">2015</xref>).</p><p id="Par5">Patients suffering either from diabetes type 1 or 2, or developing hypertension, often receive blood pressure reducing ACE inhibitors and angiotensin II type I receptor blockers, which may lead to ACE2 overexpression. Therefore, although clinical evidence is lacking, it has to be kept in mind that ACE2 upregulation might be at the origin of a higher susceptibility for developing COVID-19 (Fang et al. <xref ref-type="bibr" rid="CR9">2020</xref>; Fitzgerald <xref ref-type="bibr" rid="CR10">2020</xref>). Furthermore, these patients often suffer from the metabolic syndrome, which is a major risk factor for non-alcoholic fatty liver disease (NAFLD). NAFLD can sensitize the liver for hepatotoxicants such as acetaminophen (Michaut et al. <xref ref-type="bibr" rid="CR22">2014</xref>; Massart et al. <xref ref-type="bibr" rid="CR21">2017</xref>), which is the advised and widely used anti-pyretic symptomatic drug treatment. Although it is actually not known whether a link exists between COVID-19 and liver steatosis, it is worrying that in a recent <italic>post-mortem</italic> histopathological analysis of a liver biopsy of a COVID-19 patient microvesicular liver steatosis was observed (Xu et al<italic>.</italic><xref ref-type="bibr" rid="CR27">2020a</xref>, <xref ref-type="bibr" rid="CR28">b</xref>). Even though this finding needs to be confirmed in larger studies, it has also been demonstrated that patients suffering from COVID-19 exhibited increased serum levels of monocyte chemoattractant protein-1 (MCP-1) (Huang et al. <xref ref-type="bibr" rid="CR15">2020</xref>), which is a chemokine known to exacerbate steatohepatitis (Gao and Tsukamoto <xref ref-type="bibr" rid="CR2">2016</xref>). Consequently, pre-disposing factors for developing steatohepatitis, such as intake of steatosis-inducing drugs (<italic>e.g.</italic> sodium valproate, amiodarone, tamoxifen and methotrexate) (Boeckmans et al. <xref ref-type="bibr" rid="CR3">2018</xref>), could play a role in combined COVID-19 and DILI. Knowing that liver dysfunction and NAFLD are more common in the elderly, who are also more prone to develop severe COVID-19, it is probably wise to carefully monitor COVID-19 patients for drug treatment that could lead to DILI.</p><p id="Par6">In vitro methodologies are well-positioned to study potential DILI of compounds currently being developed against COVID-19. Relatively simple human-relevant cell models can be used to evaluate hepatotoxic properties of (novel) drugs in a relatively short time. This has been robustly demonstrated for a large series of compounds (Rodrigues et al. <xref ref-type="bibr" rid="CR25">2016</xref>; Kuna et al. <xref ref-type="bibr" rid="CR16">2018</xref>). Also co-morbidities such as NAFLD that increase the risk for developing DILI can be modeled using in vitro methodology (Massart et al. <xref ref-type="bibr" rid="CR21">2017</xref>; Boeckmans et al. <xref ref-type="bibr" rid="CR4">2019</xref>). Recently, Huh7 and Vero E6 cells in culture have been used to assess the pharmacological effects of remdesivir, chloroquine and hydroxychloroquine, all potential anti-COVID-19 treatments under study (Liu et al. <xref ref-type="bibr" rid="CR17">2020a</xref>; Wang et al. <xref ref-type="bibr" rid="CR26">2020</xref>). Hence, in vitro methodologies can be easily explored for increasing our knowledge with respect to the pharmacological concern and concomitant toxicological aspects of COVID-19 treatment.</p><p id="Par7">Overall, despite the indications that SARS-CoV-2 infection might have an influence on normal hepatic functions and the fact that drugs are used for the treatment of COVID-19 that have proven hepatotoxic properties (whether or not due to overdosing), more mechanistic studies regarding SARS-CoV-2 entry and replication in liver cells and the potential consequences of medication for vital organs, including the liver, are warranted.</p></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p id="Par8">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Hubscher</surname><given-names>SG</given-names></name></person-group><article-title>Systemic viral infections and collateral damage in the liver</article-title><source>Am J Pathol</source><year>2006</year><volume>168</volume><fpage>1057</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2006.051296</pub-id><?supplied-pmid 16565481?><pub-id pub-id-type="pmid">16565481</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckmans</surname><given-names>J</given-names></name><name><surname>Natale</surname><given-names>A</given-names></name><name><surname>Buyl</surname><given-names>K</given-names></name><etal/></person-group><article-title>Human-based systems: mechanistic NASH modelling just around the corner?</article-title><source>Pharmacol Res</source><year>2018</year><volume>134</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.06.029</pub-id><?supplied-pmid 29964161?><pub-id pub-id-type="pmid">29964161</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckmans</surname><given-names>J</given-names></name><name><surname>Buyl</surname><given-names>K</given-names></name><name><surname>Natale</surname><given-names>A</given-names></name><etal/></person-group><article-title>Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH</article-title><source>Pharmacol Res</source><year>2019</year><volume>144</volume><fpage>377</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.04.016</pub-id><?supplied-pmid 31028903?><pub-id pub-id-type="pmid">31028903</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonacini</surname><given-names>M</given-names></name></person-group><article-title>Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1086/381453</pub-id><pub-id pub-id-type="pmid">14679456</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-NCoV infection</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.03.931766</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><etal/></person-group><article-title>Clinical and immunologic features in severe and moderate coronavirus disease 2019</article-title><source>J Clin Invest</source><year>2020</year><pub-id pub-id-type="doi">10.1172/JCI137244</pub-id><?supplied-pmid 32250342?><pub-id pub-id-type="pmid">32250342</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: retrospective analysis</article-title><source>World J Gastroenterol</source><year>2004</year><volume>10</volume><fpage>1652</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.3748/wjg.v10.i11.1652</pub-id><?supplied-pmid 15162543?><pub-id pub-id-type="pmid">15162543</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Karakiulakis</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source>Lancet Respir Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id><?supplied-pmid 32222169?><pub-id pub-id-type="pmid">32222169</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>GA</given-names></name></person-group><article-title>Misguided drug advice for COVID-19</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1434</fpage><pub-id pub-id-type="doi">10.1126/science.abb8034</pub-id><?supplied-pmid 32198292?><pub-id pub-id-type="pmid">32198292</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name></person-group><article-title>Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><fpage>1704</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.01.025</pub-id><?supplied-pmid 26826669?><pub-id pub-id-type="pmid">26826669</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>J</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id><?supplied-pmid 7102549?><pub-id pub-id-type="pmid">7102549</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><?supplied-pmid 32220206?><pub-id pub-id-type="pmid">32220206</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurwitz</surname><given-names>D</given-names></name></person-group><article-title>Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics</article-title><source>Drug Dev Res</source><year>2020</year><pub-id pub-id-type="doi">10.1002/ddr.21656</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. a first step in understanding SARS pathogenesis</article-title><source>J Pathol</source><year>2004</year><volume>203</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/path.1570</pub-id><?supplied-pmid 15141377?><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuna</surname><given-names>L</given-names></name><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Kizivat</surname><given-names>T</given-names></name><etal/></person-group><article-title>Models of drug induced liver injury (DILI)&#x02014;current issues and future perspectives</article-title><source>Curr Drug Metab</source><year>2018</year><volume>19</volume><fpage>830</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.2174/1389200219666180523095355</pub-id><?supplied-pmid 29788883?><pub-id pub-id-type="pmid">29788883</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id><?supplied-pmid 32194981?><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Tao</surname><given-names>ZW</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease</article-title><source>Chin Med J (Engl)</source><year>2020</year><pub-id pub-id-type="doi">10.1097/CM9.0000000000000775</pub-id><?supplied-pmid 32187045?><pub-id pub-id-type="pmid">32187045</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makin</surname><given-names>AJ</given-names></name><name><surname>Wendon</surname><given-names>J</given-names></name><name><surname>Fitt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fulminant hepatic failure secondary to hydroxychloroquine</article-title><source>Gut</source><year>1994</year><volume>35</volume><fpage>569</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1136/gut.35.4.569</pub-id><?supplied-pmid 8175002?><pub-id pub-id-type="pmid">8175002</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>MA</given-names></name><name><surname>Vuppalanchi</surname><given-names>R</given-names></name><name><surname>Fontana</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Clinical and histologic features of azithromycin-induced liver injury</article-title><source>Clin Gastroenterol Hepatol</source><year>2015</year><volume>13</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2014.07.054</pub-id><?supplied-pmid 25111234?><pub-id pub-id-type="pmid">25111234</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massart</surname><given-names>J</given-names></name><name><surname>Begriche</surname><given-names>K</given-names></name><name><surname>Moreau</surname><given-names>C</given-names></name><etal/></person-group><article-title>Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity</article-title><source>J Clin Transl Res.</source><year>2017</year><volume>3</volume><fpage>212</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.18053/jctres.03.2017S1.006</pub-id><?supplied-pmid 28691103?><pub-id pub-id-type="pmid">28691103</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaut</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>C</given-names></name><name><surname>Robin</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease</article-title><source>Liver Int</source><year>2014</year><volume>34</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/liv.12514</pub-id><pub-id pub-id-type="pmid">24164713</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naidoo</surname><given-names>K</given-names></name><name><surname>Hassan-Moosa</surname><given-names>R</given-names></name><name><surname>Mlotshwa</surname><given-names>P</given-names></name><etal/></person-group><article-title>High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB tri</article-title><source>Clin Infect Dis</source><year>2019</year><pub-id pub-id-type="doi">10.1093/cid/ciz732</pub-id><?supplied-pmid 31761933?><pub-id pub-id-type="pmid">31761933</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raoult</surname><given-names>D</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Coronavirus infections: epidemiological, clinical and immunological features and hypotheses</article-title><source>Cell Stress</source><year>2020</year><volume>4</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.15698/cst2020.04.216</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>RM</given-names></name><name><surname>Heymans</surname><given-names>A</given-names></name><name><surname>De Boe</surname><given-names>V</given-names></name><etal/></person-group><article-title>Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems</article-title><source>Toxicol Lett</source><year>2016</year><volume>240</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2015.10.014</pub-id><?supplied-pmid 26497421?><pub-id pub-id-type="pmid">26497421</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-NCoV) in vitro</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><?supplied-pmid 7054408?><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Liver injury during highly pathogenic human coronavirus infections</article-title><source>Liver Int</source><year>2020</year><pub-id pub-id-type="doi">10.1111/liv.14435</pub-id><?supplied-pmid 32187823?><pub-id pub-id-type="pmid">32187823</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id><?supplied-pmid 32109425?><pub-id pub-id-type="pmid">32109425</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Liver injury in COVID-19: management and challenges</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30057-1</pub-id><?supplied-pmid 32192627?><pub-id pub-id-type="pmid">32192627</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><?supplied-pmid 32251621?><pub-id pub-id-type="pmid">32251621</pub-id></element-citation></ref></ref-list></back></article>